Stifel Downgrades Immunovant to Hold, Lowers Price Target to $9
Stifel analyst Derek Archila downgrades Immunovant (NASDAQ:IMVT) from Buy to Hold and lowers the price target from $28 to $9.
‘SPACs Attack’ Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs. Here is a look back at the week in SPACs for deals, rumors and headline news all covered on Benzinga’s “SPACs Attack.”